Patents by Inventor Lars Blumenstein

Lars Blumenstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSAGE REGIMEN FOR A PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR
    Publication number: 20180280370
    Abstract: A method of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of a phosphatidylinositol 3-kinase inhibitor compound or a pharmaceutically acceptable salt thereof once-per-day either on a continuous daily schedule or an intermittent schedule at about zero to about three hours prior to sleep; a therapeutic regimen comprising administration of said compound or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.
    Type: Application
    Filed: October 31, 2016
    Publication date: October 4, 2018
    Inventors: Christian Schnell, Christine Fritsch, Emmanuelle di Tomaso, Cristian Massacesi, Lars Blumenstein
  • Pyridopyrazine derivatives and their use
    Patent number: 8912189
    Abstract: The present invention provides new pyridopyrazine compounds of Formula (I) which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: December 16, 2014
    Assignee: Aeterna Zentaris GmbH
    Inventors: Matthias Gerlach, Irene Seipelt, Lars Blumenstein, Gilbert Mueller, Eckhard Guenther, Tilmann Schuster, Michael Teifel
  • Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors
    Patent number: 8791118
    Abstract: The invention provides new pyridopyrazine compounds according to formula (I) which are highly selective as Ras-Raf-Mek-Erk signal transduction pathway inhibitors and in particular are highly selective Erk inhibitors.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: July 29, 2014
    Assignee: Aeterna Zentaris GmbH
    Inventors: Matthias Gerlach, Irene Seipelt, Lars Blumenstein, Gilbert Mueller, Eckhard Guenther, Tilmann Schuster, Michael Teifel
  • Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors
    Patent number: 8546435
    Abstract: The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: October 1, 2013
    Assignees: AEterna Zentaris GmbH, Centre National de la Recherche Scientifique, University of Montpellier I, University of Montpellier II
    Inventors: Babette Aicher, Gilbert Mueller, Klaus Paulini, Lars Blumenstein, Peter Schmidt, Matthias Gerlach, Michael Teifel, Jean Martinez, Jean-Alain Fehrentz, Anne-Laure Blayo
  • PYRIDOPYRAZINE DERIVATIVES AND THEIR USE
    Publication number: 20120258080
    Abstract: The present invention provides new pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.
    Type: Application
    Filed: April 4, 2012
    Publication date: October 11, 2012
    Applicant: AETERNA ZENTARIS GmbH
    Inventors: Matthias GERLACH, Irene SEIPELT, Lars BLUMENSTEIN, Gilbert MUELLER, Eckhard GUENTHER, Tilmann SCHUSTER, Michael TEIFEL
  • PYRIDOPYRAZINE DERIVATIVES AND THEIR USE
    Publication number: 20120259151
    Abstract: The present invention provides new pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.
    Type: Application
    Filed: April 4, 2012
    Publication date: October 11, 2012
    Applicant: AETERNA ZENTARIS GmbH
    Inventors: Matthias GERLACH, Irene Seipelt, Lars Blumenstein, Gilbert Mueller, Eckhard Guenther, Tilmann Schuster, Michael Teifel
  • NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS
    Publication number: 20120083494
    Abstract: The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors.
    Type: Application
    Filed: September 16, 2011
    Publication date: April 5, 2012
    Applicants: AETERNA ZENTARIS GmbH, University of Montpellier Il, University of Montpellier I, Centre National De La Recherche Scient.
    Inventors: Babette Aicher, Gilbert Mueller, Klaus Paulini, Lars Blumenstein, Peter Schmidt, Matthias Gerlach, Michael Teifel, Jean Martinez, Jean-Alain Fehrentz, Anne-Laure Blayo